Phantom Neuro Inc.


Developer of a minimally invasive muscle–machine interface intended to provide real-time control of robotic prostheses and exoskeletons. The company designs implantable low-profile muscle sensors with embedded electronics, machine-learning signal-processing software for real-time decoding of muscle activity, clinical studies and a patient registry for trial recruitment, and pursues regulatory approvals to enable outpatient implantation and broader clinical use.

Industries

biotechnology
medical
neuroscience-e37a
robotics

Nr. of Employees

small (1-50)


Products

Minimally invasive muscle–machine interface platform (implantable sensor + decoding software)

A platform consisting of a subcutaneous low-profile muscle sensor with embedded electronics and accompanying signal-processing and machine-learning software to decode muscle activity into real-time control commands for robotic prostheses and exoskeletons.


Services

A registry to enroll and notify amputees and other candidates about upcoming clinical study opportunities and trials.

Design and execution of non-invasive and clinical validation studies to measure decoding accuracy, latency, and real-world function of control systems.

Expertise Areas

  • Minimally invasive neural interfaces
  • EMG-based prosthesis control
  • Real-time signal processing and machine learning for biosignals
  • Clinical study execution and patient recruitment
  • Show More (2)

Key Technologies

  • Multi-electrode electromyography (EMG) arrays
  • Implantable low-profile muscle sensors with embedded electronics
  • Real-time ML-based signal decoding
  • Mobile and cloud integration for robotics control
  • Show More (2)

News & Updates

Launch of a patient registry to connect amputees with upcoming clinical opportunities.

Secured $19M Series A funding led by a strategic investor to advance neural interface development for prosthetics and robotics.

Report of the ASCENT study showing 94% gesture decoding accuracy across 11 hand and wrist movements and average latency under 200 ms in surface-sensor testing.

Multiple press articles covering funding, technology demonstrations, and company progress.

Company reports receiving Breakthrough Device designation and TAP program acceptance from the FDA for its minimally invasive interface platform.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.